Factors associated with clopidogrel use, adherence, and persistence in patients with acute coronary syndromes undergoing percutaneous coronary intervention

The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents

(2009) Michelle J. Butler et al.   AMERICAN HEART JOURNAL

Clinical Outcomes of Patients With Diabetic Nephropathy Randomized to Clopidogrel Plus Aspirin Versus Aspirin Alone (A post hoc Analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA] Trial)

(2009) Arijit Dasgupta et al.   AMERICAN JOURNAL OF CARDIOLOGY

Predictors of Early Discontinuation of Evidence-Based Medicine After Acute Coronary Syndrome

(2009) Chiara Melloni et al.   AMERICAN JOURNAL OF CARDIOLOGY

Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation

(2009) Ankie Harmsze et al.   Pharmacogenetics and Genomics

Initiation and persistence with clopidogrel treatment after acute myocardial infarction - a nationwide study

(2008) Rikke Sørensen et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38

(2008) Stephen D. Wiviott et al.   CIRCULATION